KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell

EP: 2.Challenges in Treating RCC From Community and Academic Settings

EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

Now Viewing

EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

EP: 5.nccRCC: Alternative Therapies

EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC

EP: 7.AE Management of IO/TKI and Future of nccRCC

EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

EP: 9.NCCN Guideline Updates in Clear-Cell RCC

EP: 10.Best Treatment Selection in Clear-Cell RCC

Video content above is prompted by the following:

• Discuss the long-term follow-up data from the phase II 2 KEYNOTE-B61trial investigating pembrolizumab and lenvatinib and its the data’s impact in the first-line setting for advanced nccRCC.
  • How does the population size of this trial compare to with others?

Please comment on the recent label change based on this these data.

• Building on the long-term follow-up data from the KEYNOTE-B61 trial, how did the response rates and safety data compare across different nccRCC histologies?

1. In your practice, how do you approach dose reductions and treatment duration management?

How does the safety data seen in KEYNOTE B61 compare to with what is was seen in the CLEAR trial?